Skip Navigation

Visiting Dana-Farber? See our prescreening and mask requirements.

Our Approach to BPDCN Treatment

  • Andrew Lane, MD, PhD, Director of the BPDCN Center, consults with a patient

    Andrew Lane, MD, PhD, director of the BPDCN Center, consults with a patient

  • Because BPDCN can affect the bone marrow, blood, lymph nodes, and skin, your care involves a multidisciplinary team. From pathologists involved in diagnosis to oncologists and dermatologists who lead the treatment team, our experts use novel approaches to the evaluation, diagnosis, and treatment of patients with BPDCN. This team takes a patient-centered approach to your care, with your needs as the focus of all they do.

    Evaluation and diagnosis

    Techniques for diagnosing BPDCN include:

    • Biopsy, performed by our dermatologists, interventional radiologists, or surgical oncologists
    • Genetic analysis
    • Radiology
    • Laboratory testing
    • Molecular testing using immunohistochemistry and/or flow cytometry
    • Cytogenetics including chromosomal karyotype, flow cytometry to help differentiate BPDCN from other leukemias or lymphomas.

    Often, patients have had biopsies elsewhere before coming to our Center. But whether performed here or elsewhere, our pathologists review all initial biopsies.

    Dermatologists may also perform skin biopsies to establish the diagnosis, to see if the disease is affecting the skin, or to monitor response to treatment.

    Personalized treatment plans

    Treatment for BPDCN begins with chemotherapy or targeted therapy, sometimes followed by a stem cell transplant. Some patients participate in a clinical trial exploring new treatments for BPDCN, either as their first treatment or later in their treatment journey. Dana-Farber was one of the leaders of a recent clinical trial for BPDCN evaluating a targeted immunotoxin called tagraxofusp (also known as Elzonris or SL-401), a novel agent that targets the IL-3 receptor (CD123), which is present on the surface of tumor cells in all cases of BPDCN. This research led to tagraxofusp becoming the first approved drug specifically for BPDCN.

    Our physician-researchers are exploring additional therapeutic approaches and more clinical trials may soon be available. Read more about our research on BPDCN.

    Compassionate care and support

    We understand that cancer affects patients and their families in many ways. So, in addition to providing highly personalized care and attention from our doctors, nurses, technicians, and staff, our Center offers a wide range of services, before, during, and after treatment. Support programs and resources that help patients and families include:

    • Financial planning
    • Nutrition counseling
    • Integrative therapies, including massage and acupuncture
    • Support groups led by our social workers
  • Care and Support at Dana-Farber

    healthy smoothies

    Eating Well During Cancer Video Series

    This video series and resource toolkit features Dana-Farber nutrition specialist Stacy Kennedy, MPH, RD, CSO, LDN, and explores how diet can help support your health and wellbeing during and after cancer treatment.

    Blum Center creative arts program participant

    The Eleanor and Maxwell Blum Patient and Family Resource Center

    The Blum Resource Center provides patients and family members with a comfortable environment to learn more about disease treatment and management.

    flower in the Healing Garden

    Integrative Therapies Education Series

    Learn more about the Zakim Center's many integrative therapies that help patients feel better by reducing anxiety and pain.